Literature DB >> 25768337

A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence.

Zhaoping Li1, Yue Yu, Huanhuan Zhang, Guifa Xu, Liyong Chen.   

Abstract

OBJECTIVE: The purpose of this systematic meta-analysis was to evaluate the diagnostic accuracy of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for the assessment of glioma recurrence and compare it with that of (18)F-fluorodeoxyglucose ((18)F-FDG) PET.
METHODS: The authors electronically and manually searched for studies from 1948 to 2014 that evaluated the diagnostic accuracy of (18)F-FDG or (18)F-FLT PET for glioma recurrence. The primary results of sensitivity, specificity, and diagnostic odds ratio (DOR) were summarized using the random-effects model. Summary receiver operating characteristic (ROC) curves and its area under the curve (AUC were used to summarize the overall diagnostic accuracy. Statistical analysis was performed with the software STATA (version 11.0).
RESULTS: Twenty-four studies that included a total of 799 patients were included in the meta-analysis. The pooled sensitivity, specificity, DOR, and summary ROC AUC for the overall diagnostic accuracy of (18)F-FDG PET were 0.78 (95% CI 0.69-0.85), 0.77 (95% CI 0.66-0.85), 12 (95% CI 6-22), and 0.84 (95% CI 0.81-0.87), respectively. The pooled sensitivity, specificity, DOR, and summary ROC AUC for the overall diagnostic accuracy of (18)F-FLT PET were 0.82 (95% CI 0.51-0.95), 0.76 (95% CI 0.50-0.91), 15 (95% CI 4-56), and 0.85 (95% CI 0.81-0.88), respectively. Metaregression analysis showed that year of publication, male proportion, average age, and blinding review did not affect the test performance statistically significantly (all P > 0.05).
CONCLUSION: This meta-analysis indicates that PET by using (18)F-FLT has a moderately better overall accuracy for diagnosing glioma recurrence compared with that by using (18)F-FDG. Video abstract: http://links.lww.com/NMC/A41.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25768337     DOI: 10.1097/MNM.0000000000000302

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

1.  PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors.

Authors:  Lance T Hall; Benjamin Titz; H Ian Robins; Bryan P Bednarz; Scott B Perlman; Jamey P Weichert; John S Kuo
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

2.  [124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors.

Authors:  Lance T Hall; Benjamin Titz; Nishanta Baidya; Anja G van der Kolk; H Ian Robins; Mario Otto; Scott B Perlman; Jamey P Weichert; John S Kuo
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

3.  Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging.

Authors:  B Sacconi; R A Raad; J Lee; H Fine; D Kondziolka; J G Golfinos; J S Babb; R Jain
Journal:  J Neurooncol       Date:  2016-01-04       Impact factor: 4.130

Review 4.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

Review 5.  An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care.

Authors:  Hossein Shooli; Habibollah Dadgar; Yì-Xiáng J Wáng; Manochehr Seyedi Vafaee; Saman Rassaei Kashuk; Reza Nemati; Esmail Jafari; Iraj Nabipour; Ali Gholamrezanezhad; Majid Assadi; Mykol Larvie
Journal:  Quant Imaging Med Surg       Date:  2019-09

Review 6.  18F-fluorothymidine PET imaging in gliomas: an update.

Authors:  Alexandra Nikaki; George Angelidis; Roxani Efthimiadou; Ioannis Tsougos; Varvara Valotassiou; Konstantinos Fountas; Vasileios Prasopoulos; Panagiotis Georgoulias
Journal:  Ann Nucl Med       Date:  2017-06-13       Impact factor: 2.668

7.  An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma.

Authors:  Kalevi Kairemo; Gregory C Ravizzini; Homer A Macapinlac; Vivek Subbiah
Journal:  Diagnostics (Basel)       Date:  2017-04-04

Review 8.  Imaging in neuro-oncology.

Authors:  Hari Nandu; Patrick Y Wen; Raymond Y Huang
Journal:  Ther Adv Neurol Disord       Date:  2018-02-28       Impact factor: 6.570

9.  Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models.

Authors:  Patrick L Donabedian; Susanne Kossatz; John A Engelbach; Stephen A Jannetti; Brandon Carney; Robert J Young; Wolfgang A Weber; Joel R Garbow; Thomas Reiner
Journal:  EJNMMI Res       Date:  2018-07-04       Impact factor: 3.138

10.  18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.

Authors:  Christy L Osgood; Mohammed N Tantawy; Nichole Maloney; Zachary B Madaj; Anderson Peck; Elissa Boguslawski; Jennifer Jess; Jason Buck; Mary E Winn; H Charles Manning; Patrick J Grohar
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.